| http://www.w3.org/ns/prov#value | - Thus, any regulatory agency, such as the FDA or the EMEA, must find the optimal speed/safety combination that efficiently balances the gains of more rapid access to drugs against the increased probability of unsafe drugs being introduced into the market.
|
